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Abstract
Background The gut environment has been considered to
play a role in the development of nonalcoholic steatohep-
atitis (NASH). a-glucosidase inhibitors (a-GIs) delay car-
bohydrate absorption and may change the gut environment.
We considered that the protective effect of a-GIs against
NASH development is related to changes in the gut envi-
ronment and thus investigated the effects of miglitol, an a-
GI, on NASH development and the gut environment.
Methods Mice were divided into three groups and fed a
normal chow diet (NCD), a high-fat high-sucrose diet
(HFHSD), or HFHSD plus 0.04% miglitol (HFHSD plus
M) for 12 weeks.
Results Insulin resistance developed more in the HFHSD
group than in the NCD group, whereas it was suppressed in
the HFHSD plus M group. NASH was evaluated histologi-
cally, biochemically, and on the basis of messenger RNA
expression levels. Miglitol treatment suppressed HFHSD-
induced NASH development with the suppression of hepatic
Toll-like receptor 4 expression, increased glucagon-like
peptide 1 (GLP-1) concentration, and reduced lipopolysac-
charide concentration in portal plasma. Regarding the gut
environment, the intestinal transit time was shortened and
colon inflammation was suppressed in the HFHSD plus M
group compared with the HFHSD group. Regarding the gut
microbiota, the abundances of Erysipelotrichaceae and
Coriobacteriaceae were increased in the HFHSD group
compared with the NCD group, whereas the increase was
suppressed in the HFHSD plus M group.
Conclusions We demonstrated that miglitol has a protec-
tive effect against HFHSD-induced NASH development.
The increased GLP-1 secretion and the suppression of
endotoxemia, associated with the changes in the gut envi-
ronment, including the gut microbiota, could contribute to
the underlying mechanisms.
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Introduction
The prevalence of nonalcoholic fatty liver disease
(NAFLD) has been increasing worldwide, along with the
increase in the number of people with obesity and
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metabolic syndrome. Approximately 10–20% of patients
with NAFLD are estimated to have nonalcoholic steato-
hepatitis (NASH), characterized by hepatocellular lipid
accumulation along with inflammation and fibrosis [1–3].
Traditionally, the two-hit theory has been accepted as a
mechanism of NASH pathogenesis. According to this
theory, lipid accumulation in hepatocytes (first hit) is a
prerequisite for a second hit, such as oxidative stress,
inflammatory cytokines, and endotoxins [4]. This view has
been challenged recently by a multiple parallel-hit
hypothesis that proposes that multiple hits act together, not
independently, in the development of NASH [5]. NASH
can lead to cirrhosis and liver cancer; therefore, there is an
essential need for therapeutic interventions. However, the
current standard treatment of NASH is limited to weight
reduction through lifestyle interventions, including dietary
modifications and bariatric surgery [6, 7]. a-glucosidase
inhibitors (a-GIs) are antidiabetics that delay the absorp-
tion of carbohydrates from the small intestine by inhibiting
degradation of disaccharides to monosaccharides, thereby
providing a postprandial blood glucose lowering effect.
Acarbose, voglibose, and miglitol are the a-GIs that are
currently used in clinical practice [8]. a-GIs can enhance
the production of butyrate (a short-chain fatty acid) in feces
[9] and shorten the intestinal transit time in humans [10].
These findings suggest that a-GIs can change the gut
environment. On the other hand, there are studies reporting
a prolonged intestinal transit time, increased intestinal
permeability, and altered gut microbiota in patients with
NAFLD/NASH, which may indicate changes in their gut
environment [11–13]. In addition, a-glucosidase activity
reportedly increased in the intestinal tract in high-fat-diet-
induced obese rats [14]. It has also been reported that
acarbose showed a protective effect against NASH devel-
opment in high-fat-induced obese rats [15]. However, the
mechanisms of these effects have not been fully elucidated.
We considered that the protective effects of a-GIs against
NASH development were related to changes in the gut
environment. Thus, we investigated the effects of miglitol
on NASH development and the gut environment using a




Five-week-old male C57BL/6 mice were purchased from
Charles River Japan (Kanagawa, Japan). The mice were
housed in temperature- and light-controlled rooms with
free access to food and water. At 6 weeks of age, the mice
were divided into three groups (n = 10 per group) and fed,
respectively, a normal chow diet (NCD; 12.7 kcal% fat,
61.6 kcal% carbohydrate, and 25.7 kcal% protein),
HFHSD (44.6 kcal% fat, 40.6 kcal% carbohydrate, and
14.8 kcal% protein), or HFHSD containing 0.04% miglitol
(HFHSD plus M) for 12 weeks. The HFHSD was prepared
by Oriental Yeast (Tokyo, Japan) according to the method
described in a previous study [16]. Miglitol was supplied
by Sanwa Kagaku Kenkyusho (Aichi, Japan). The mice
were killed after having fasted for 6 h; portal blood, the
liver, and the colon were then collected, and the fecal
contents of the entire large intestine were weighed. The
mice were handled in accordance with the guidelines for
the care and use of experimental animals published by the
Japanese Association for Laboratory Animal Science, and
animal experiments were performed in strict accordance
with the recommendations in the Guide for the Care and
Use of Laboratory Animals of the Hiroshima University
Animal Research Committee. All protocols were approved
by the Institutional Review Board of Hiroshima University.
Histochemical studies
Paraffin-embedded liver and colon sections were stained
with hematoxylin–eosin (HE), Sirius red, and an antibody
for a-smooth muscle actin at Kyodo Byori (Kobe, Japan).
Images were obtained with a multifunctional microscope
(BZ-9000; Keyence, Osaka, Japan). Evaluation of disease
progression was performed according to the histological
scoring system for NAFLD [17], and the number of posi-
tively stained areas was counted in 12 randomly selected
fields (920 or 940) and analyzed with use of the BZ-9000
microscope.
Biochemical analysis
The blood glucose level was measured with a Medisafe
mini system (Terumo, Tokyo, Japan). The plasma insulin
level was measured with a mouse insulin ELISA kit
(Sibayagi, Gunma, Japan). Homeostatic model assessment
insulin resistance (HOMA-IR) was calculated as fasting
insulin (mU/L) 9 fasting glucose (mmol/L)/22.5 [18].
Hepatic lipids were extracted and assayed by the Folch
method [19]. The hepatic triglyceride content was assayed
with the triglyceride E test (Wako, Osaka, Japan). The
plasma alanine aminotransferase level was measured with
a transaminase C-II test kit (Wako, Osaka, Japan). The
plasma active glucagon-like peptide 1 (GLP-1) concen-
tration was measured with a mouse active GLP-1 ELISA
kit (Shibayagi, Gunma, Japan). The plasma lipopolysac-
charide-binding protein (LBP) concentration was mea-
sured with an enzyme immunoassay for the determination
of mouse LBP (Biometec, Greifswald, Germany). The
plasma lipopolysaccharide (LPS) concentration was
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measured with a mouse LPS ELISA kit (Cusabio, Wuhan,
China).
Quantitative real-time reverse transcription PCR
Total RNA was extracted from mouse livers and colons
with use of TRIzol (Invitrogen, Carlsbad, CA, USA). First-
strand DNA was synthesized with PrimeScript RT master
mix (Takara, Kyoto, Japan). Quantitative real-time reverse
transcription PCR was performed with SYBR Green master
mix (Takara) and an ABI 7500 real-time PCR system
(Applied Biosystems, Foster City, CA, USA). The mes-
senger RNA (mRNA) gene expression levels were nor-
malized to that of the glyceraldehyde 3-phosphate
dehydrogenase gene, and relative expression was deter-
mined by the comparative Ct method. The primers,
designed as previously reported [20–24], were as follows:
glyceraldehyde 3-phosphate dehydrogenase forward
TGATGGGTGTGAACCACGAG, reverse GGGCCATCC
ACAGTCTTCTG; fatty acid synthase forward GCTGCGG
AAACTTCAGGAAAT, reverse AGAGACGTGTCACTC
CTGGACTT; carnitine palmitoyltransferase 1 forward
CCAGGCTACAGTGGGACATT, reverse GAACTTGCC
CATGTCCTTGT; CD36 forward TGCTGGAGCTGTTA
TTGGTG, reverse TGGGTTTTGCACATCAAAGA;
tumor necrosis factor a forward GTAGCCCACGTCGTA
GCAAAC, reverse CTGGCACCACTAGTTGGTTGTC;
IL-1b forward TGGGCCTCAAAGGAAAGAAT, reverse
CTTGGGATCCACACTCTCCA; transforming growth
factor b forward ATTCCTGGCGTTACCTTG, reverse
CTGTATTCCGTCTCCTTGGTT; Toll-like receptor 4
(TLR4) forward GCCTTTCAGGGAATTAAGCTCC,
reverse AGATCAACCGATGGACGTGTAA; CD14 for-
ward GAGTTGTGACTGGCCCAGTCAGC, reverse GCA




Carmine red (10 mg per liter of water, 10 lL per gram of
body weight) was administered orally to each mouse. The
total intestinal transit time was defined as the time between
the ingestion of carmine red and the first appearance of
colored feces.
Gut microbiota analyses by next-generation
sequencing
Fresh feces were collected immediately after defecation,
frozen, and stored for gut microbiota analyses after
12 weeks of the diet. Total DNA was extracted from frozen
feces with use of a QIAamp DNA stool mini Kit (Qiagen,
Valencia, CA, USA) as previously described [25]. For each
sample, the V3–V4 region of the 16S ribosomal RNA
(rRNA) gene was amplified with use of primer pairs 341F
(50-TCGTCGGCAGCGTCAGATGTGTATAAGAGA-
CAGCCTACGGGAGGCAGCAG-30) and 785R (50-
GTCTCGTGGGCTCGGAGATGTGTATAAGAGA-
CAGGACTACCAGGGTATCTAATCC-30), with Illumina
adapter overhang nucleotide sequences as indicated by the
underlines. Amplicons were purified, indexed, and
sequenced according to the ‘‘16S Metagenomic Sequencing
Library Preparation’’ protocol. We used the software pro-
gram QIIME (version 1.8.0) [26] to analyze the 16S rRNA
sequence generated from paired-end amplicon sequencing.
Paired Illumina reads were assembled with QIIME’s fastq-
join. All reads from paired end sequencing were quality
filtered with use of QIIME’s script split_libraries_fastq.py.
Chimera detection was performed with USEARCH version
6.1 [27] against the 97% clustered representative sequences
from GreenGenes version 13.8 [28]. Operational taxo-
nomic unit data were generated with pick_open_refer-
ence_otus.py with use of the default uclust method and
GreenGenes version 13.8. Subsequent analyses of diversity
were performed at a depth of 10,000 sequences per sample.
Alpha diversity was assessed by the Shannon index. Beta
diversity was studied by a principal coordinates analysis,
measuring dissimilarities at phylogenetic distance based on
weighted Unifrac analysis. We also used QIIME to esti-
mate the relative abundance of bacterial groups at different
taxonomic levels between each group of mice.
Statistical analysis
Results are expressed as the mean ± standard error of the
mean. Statistical significance was assessed by ANOVA
followed by the Tukey honestly significant difference test.
Statistical analyses were performed with IBM SPSS
Statistics version 22.0 (IBM, Armonk, NY, USA) or R
(version 3.1.3; R Foundation for Statistical Computing,
Vienna, Austria). We took p\ 0.05 to indicate a statisti-
cally significant difference.
Results
Miglitol treatment suppressed HFHSD-induced
NASH development
To evaluate the protective effects of miglitol against NASH
development, the mice were fed the NCD, HFHSD, or
HFHSD plus M for 12 weeks. The HFHSD group showed
increased body weight and food intake compared with the
NCD group, but there were no significant differences
between the HFHSD group and the HFHSD plus M group
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(Fig. 1a, b). The HFHSD group showed increased levels of
fasting blood glucose and HOMA-IR compared with the
NCD group, whereas these changes were suppressed in the
HFHSD plus M group (Fig. 1c). The livers were harvested
and subjected to histological analysis. HE staining of the
livers from the HFHSD group showed accumulation of
lipid droplets, inflammatory cell infiltration, and an
increase in the numbers of ballooning hepatocytes com-
pared with the NCD group, whereas these changes were
suppressed in the HFHSD plus M group (Fig. 1d). Bio-
chemical analysis revealed the hepatic triglyceride content
and plasma alanine aminotransferase levels to be higher in
the HFHSD group than in the NCD group, whereas these
changes were suppressed in the HFHSD plus M group
(Fig. 1e, f). Sirius red staining was performed to evaluate
fibrotic changes in the liver. The number of positively
stained areas increased in the HFHSD group compared
with the NCD group, whereas this increase was suppressed
in the HFHSD plus M group (Fig. 1g). Immunostaining
with a-smooth muscle actin, a marker of the activation of
stellate cells, which plays a role in liver fibrosis, showed
that the number of positively stained areas increased in the
HFHSD group compared with the NCD group, whereas this
increase was suppressed in the HFHSD plus M group
(Fig. 1h). These results showed that miglitol had protective
effects against hepatocellular lipid accumulation, inflam-
mation, and fibrosis, thereby suppressing NASH
development.
Miglitol treatment suppressed the expression
of genes involved in NASH pathogenesis
To elucidate the mechanism of the protective effects of
miglitol against NASH development, the gene expression
levels of factors related to lipid accumulation, inflamma-
tion, and fibrosis in the liver were analyzed. The mRNA
levels of fatty acid synthase (involved in fatty acid syn-
thesis) and carnitine palmitoyltransferase 1 (involved in b-
oxidation) were not significantly different among the three
groups (data not shown). The mRNA level of CD36 (in-
volved in fatty acid uptake) increased in the HFHSD group
compared with the NCD group, whereas this increase was
suppressed in the HFHSD plus M group (Fig. 2a). A pre-
vious study showed that CD36 expression in the liver was
increased by inflammatory cytokines [29]. On the basis of
this, we examined the expression of inflammatory cytoki-
nes in the liver. The mRNA levels of tumor necrosis fac-
tor a and IL-1b in the liver were increased in the HFHSD
group compared with the NCD group, whereas these
changes were suppressed in the HFHSD plus M group
(Fig. 2b). Subsequently, transforming growth factor b, a
marker of hepatic fibrosis, was analyzed. The mRNA level
of transforming growth factor b in the liver was increased
in the HFHSD group compared with the NCD group,
whereas the increase was suppressed in the HFHSD plus M
group (Fig. 2c). Finally, expression of TLR4 and CD14 (a
coreceptor for TLR4) in the liver was analyzed. The
mRNA levels of TLR4 and CD14 in the liver were
increased in the HFHSD group compared with the NCD
group, whereas these changes were suppressed in the
HFHSD plus M group (Fig. 2d).
Miglitol changed the gut environment and reduced
endotoxemia
Miglitol acts on the intestine; thus, we examined the effect
of miglitol on the gut environment. First, we examined the
effect of miglitol on the intestinal transit time. Although
there was no significant difference in the intestinal transit
time between the NCD group and the HFHSD group, the
administration of miglitol shortened the intestinal transit
time and reduced the amount of residual feces in the colon
(Fig. 3a). Inflammatory changes in the colon were also
examined. HE staining of the colon showed that signs of
early inflammation, as evidenced by submucosal edema
and inflammatory cell infiltration, were present in the
HFHSD group, whereas these changes were suppressed in
the HFHSD plus M group (Fig. 3b). The mRNA levels of
IL-1b and IL-6 in the colon also increased in the HFHSD
group compared with the NCD group, whereas these
changes were suppressed in the HFHSD plus M group
(Fig. 3c). Subsequently, portal plasma concentrations of
GLP-1, an intestinal hormone, were measured. The plasma
GLP-1 concentrations were higher in the HFHSD plus M
group than in the HFHSD group (Fig. 3d). Finally, TLR4-
signaling-related substances were examined in the portal
blood since there was a change in TLR4 expression in the
bFig. 1 Miglitol treatment suppressed high-fat high-sucrose diet
(HFHSD)-induced nonalcoholic steatohepatitis development. Mice
were divided into three groups and fed a normal chow diet (NCD),
HFHSD, or HFHSD containing 0.04% miglitol (HFHSD?M) for
12 weeks and then killed. a Weekly body weight changes (n = 10 per
group). b Weekly food intake changes (n = 10 per group). c Fasting
blood glucose levels (n = 9–10 per group) and homeostatic model
assessment insulin resistance (HOMA-IR; n = 6–9 per group).
d Liver sections were stained with hematoxylin–eosin. Scale bar
200 lm (94 magnification) or 50 lm (920 magnification). Nonal-
coholic fatty liver disease (NAFLD) activity scores were determined
for each mouse. e Hepatic triglyceride levels (n = 6–7 per group).
f Plasma alanine aminotransferase (ALT) levels (n = 6–7 per group).
g Liver sections were stained with Sirius red. Scale bar 100 lm (920
magnification). Positively stained areas were counted with use of a
Keyence BZ-9000 microscope. h Liver sections were stained with a-
smooth muscle actin (a-SMA). Scale bar 50 lm (940 magnification).
Arrows indicate a-SMA-positive areas. Positively stained areas were
counted with use of a Keyence BZ-9000 microscope. Data are
presented as the mean ± standard error of the mean. Asterisk





Fig. 2 Miglitol treatment suppressed the expression of genes
involved in nonalcoholic steatohepatitis pathogenesis. Mice were
divided into three groups and fed a normal chow diet (NCD), a high-
fat high-sucrose diet (HFHSD), or HFHSD containing 0.04% miglitol
(HFHSD?M) for 12 weeks and then killed. a Hepatic messenger
RNA (mRNA) levels of CD36 (n = 5–7 per group). b Hepatic mRNA
levels of tumor necrosis factor a (TNF-a) and IL-1b (n = 5–7 per
group). c Hepatic mRNA levels of transforming growth factor b
(TGF-b) (n = 5–7 per group). d Hepatic mRNA levels of Toll-like
receptor 4 (TLR4) and CD14 (n = 5–7 per group). Data are presented




liver. The portal plasma concentrations of LBP (a protein
required to transfer LPS to CD14) and LPS were increased
in the HFHSD group compared with the NCD group,
whereas this increase was not observed in the HFHSD plus
M group (Fig. 3e, f). These results suggest that miglitol
suppressed colon inflammation, prevented endotoxin influx
from the intestinal tract to the liver, and downregulated
TLR4 signaling in the liver.
Gut microbiota changes in response to miglitol
treatment
The effects of miglitol on the gut microbiota were exam-
ined by 16S rRNA gene sequencing. The Shannon index
was used to evaluate the diversity of gut microbiota, but
there was no significant difference in the biodiversity
among the groups (Fig. 4a). Then, principal coordinates
analysis was used to compare the gut microbial commu-
nities among the groups. The samples representing the
same group were clustered together, and those representing
different groups were clustered separately (Fig. 4b). An
analysis of similarity test showed significant differences
among the groups, suggesting that the gut microbial com-
munities were different among the three groups. The dif-
ferences in the gut microbial communities were further
examined according to bacterial classification. The per-
centage of Bacteroidetes was lower in the HFHSD group
than in the NCD group, whereas there was no significant
difference between the HFHSD group and the HFHSD plus
M group. The percentage of the Actinobacteria was higher
in the HFHSD group than in the NCD group, whereas the
increase was suppressed in the HFHSD plus M group
(Fig. 4c). Subsequently, the families of the bacteria
showing a different distribution between the HFHSD group
and the HFHSD plus M group were identified. As a result,
the percentages of the 16S rRNA gene sequences repre-
senting the Erysipelotrichaceae within the phylum Firmi-
cutes and the Coriobacteriaceae within the phylum
Actinobacteria were higher in the HFHSD group than in
the NCD group, whereas the increases were suppressed in
the HFHSD plus M group (Fig. 4d). These results sug-
gested that miglitol significantly changed the intestinal
microbial communities.
Discussion
This study demonstrates that miglitol suppressed hepato-
cellular lipid accumulation, inflammation, and fibrosis,
shortened the intestinal transit time, suppressed inflam-
mation, and changed the microbiota in the colons of
HFHSD-induced NASH mice. These protective effects of
miglitol on the liver and colon might be mediated by the
inhibition of endotoxin influx into the portal blood and by
an increase of plasma GLP-1 concentrations.
Miglitol did not reduce the body weight but reduced
insulin resistance (Fig. 1a, c). Insulin resistance is thought
to play an important role in the development of NASH
[30]. Previous studies have reported that miglitol reduced
insulin resistance in drug-naive metabolic syndrome
patients [31] and in high-fat-diet-induced obese mice [32].
These studies also reported a reduction of body weight. In
contrast, in the present study, miglitol did not reduce the
body weight but reduced HOMA-IR. Therefore, we con-
sider that a factor independent of body weight might be
involved in the mechanism of reduction of insulin resis-
tance following miglitol administration.
Endotoxin-driven TLR4 signaling is thought to be
related to insulin resistance. Several studies reported that
insulin resistance and hepatic steatosis were suppressed in
TLR4 and CD14 mutant mice [33, 34]. Endotoxin LPS
influx from the intestinal tract to the portal vein due to
enhanced intestinal permeability may induce the expres-
sion of inflammatory cytokines through TLR4 in the liver,
and thereby play an important role in the development of
NASH [35, 36]. In the present study, we showed that the
expression levels of TLR4 in the liver as well as plasma
LPS concentrations were increased in the HFHSD group
compared with the NCD group, whereas these changes
were suppressed in the HFHSD plus M group (Figs. 2d,
3f). These data suggest that the expression levels of TLR4
in the liver were increased by the HFHSD-induced influx
of LPS into the portal vein, and miglitol treatment sup-
pressed this process. Thus, protection from NASH devel-
opment by miglitol treatment appears to be at least partially






As shown in Fig. 3, the maintenance of intestinal barrier
function through suppression of colon inflammation is
considered to be one of miglitol’s protective mechanisms
of action against endotoxemia. It has been reported that
administration of an a-GI increased the levels of butyric
acid in the intestines of healthy individuals [9]. In addition,
another report demonstrated that administration of butyric
acid suppressed intestinal inflammation in mice [37]. These
findings suggest an association between the increase in the
butyric acid level in the intestine caused by miglitol and the
suppression of colon inflammation. On the other hand, it
has been reported that an a-GI shortened the intestinal
transit time in humans [10]. In the present study, miglitol
shortened the intestinal transit time and reduced the amount
of residual feces in the intestines. We have previously
reported that administration of a gastroprokinetic agent
reduced the amount of residual feces, changed the gut
microbiota, and suppressed colon inflammation in a mouse
model [23], which suggested that the effect could also
contribute to suppression of colon inflammation.
In the present study, the portal plasma GLP-1 concen-
trations were higher in the HFHSD plus M group than in
the HFHSD group (Fig. 3d). GLP-1 acts as a suppressor of
intestinal inflammation via intestinal intraepithelial lym-
phocytes [38]. It has been reported that administration of
exenatide, an analog of GLP-1, suppressed the hepatocel-
lular lipid accumulation and inflammation and suppressed
NASH development in a mouse model [39]. Therefore, we
considered that the increase in plasma GLP-1 concentra-
tions induced by miglitol might have contributed to the
suppression of NASH development by maintaining
intestinal barrier function through the suppression of
intestinal inflammation as described above and through
direct effects on the liver. In addition, several studies have
reported that miglitol increased the blood GLP-1 concen-
trations in patients with type 2 diabetes, whereas other a-
GIs did not [40, 41]. An underlying mechanism of this
effect is that unlike other a-GIs, miglitol is absorbed in the
upper part of the small intestine and can effectively stim-
ulate GLP-1 secretion, whereas most carbohydrates are
absorbed in the lower part of the small intestine, where
GLP-1-producing L cells are located [40, 41]. Therefore,
we consider that the increase in the blood GLP-1 concen-
trations is an important effect of miglitol in the suppression
of NASH development as compared with other a-GIs.
Regarding the composition of intestinal bacteria, it was
reported that acarbose increased the populations of Bifi-
dobacterium longum in Chinese patients with type 2 dia-
betes mellitus [42], which was not observed in our study,
perhaps owing to the differences between the species,
drugs, and methods of analysis. In this study, the percent-
ages of the 16S rRNA gene sequences representing the
family Erysipelotrichaceae within the phylum Firmicutes
and the family Coriobacteriaceae within the phylum
Actinobacteria were higher in the HFHSD group than in
the NCD group, whereas the increases were suppressed in
the HFHSD plus M group (Fig. 4d). Increased percentages
of Erysipelotrichaceae have been reported in mice main-
tained on a Western-style diet and in enteritis model mice,
suggesting an association of the gut microbiota with the
diet and enteritis [43] In addition, an association between
Coriobacteriaceae and hepatic triglyceride accumulation
has been reported [44]. Therefore, we consider that the
changes in the gut microbiota are related to the suppression
of intestinal inflammation and NASH development.
In conclusion, we demonstrated a protective effect of
miglitol against NASH development. The drug changed the
gut environment, including the gut microbiota, and
increased the GLP-1 secretion in the portal vein and
bFig. 3 Miglitol changed the gut environment and reduced endotox-
emia. Mice were divided into three groups and fed a normal chow diet
(NCD), a high-fat high-sucrose diet (HFHSD), or HFHSD containing
0.04% miglitol (HFHSD?M) for 12 weeks and then killed. a The
intestinal transit times were determined by measurement of the time
elapsed and the color of excreted feces. The colonic fecal weight was
determined at the time when the mice were killed (n = 10 per group).
b Colon sections were stained with hematoxylin–eosin. Scale bar
50 lm (920, 940 magnification). The straight line indicates the
extent of the submucosal edema and arrows indicate inflammatory
infiltrates composed primarily of neutrophils. c Colonic messenger
RNA (mRNA) levels of IL-1b and IL-6 (n = 4–5 per group). d Plasma
active glucagon-like peptide 1 (GLP-1) levels (n = 6–8 per group).
e Plasma lipopolysaccharide-binding protein (LBP) levels (n = 6–8
per group). f Plasma lipopolysaccharide (LPS) levels (n = 6–7 per
group). Data are presented as the mean ± standard error of the mean.
Asterisk statistical significance (p\ 0.05)
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suppressed endotoxemia. Our results suggest that miglitol
can suppress the development of NASH by improving the
gut environment.
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